Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy

Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata, Haruki Kaku, Nobuyuki Kusaka, Hiromi Kumon

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: The treatment for superficial G3 transitional cell carcinoma (TCC) of the urinary bladder remains controversial. It is important to reveal the clinical features of superficial G3 bladder cancer that can be treated conservatively. Patients and Methods: A total of 39 patients with primary superficial bladder cancer (Ta, T1) with G3 components but without concomitant carcinoma in situ (CIS), who had been treated initially with transurethral resection (TUR), were retrospectively analyzed for factors related to tumor recurrence, progression and survival. The patients were 34 males and five females whose age ranged from 49 to 85 years (average, 68 years). Initial tumor stages were Ta in one patient and T1 in 38. Initial treatments were TUR alone in 18 patients and TUR with adjuvant therapy (intravesical chemotherapy or BCG therapy) in 21. Factors examined included age, gender, morphology, size and number of tumors and adjuvant therapies. Results: Follow-up periods were 3-138 months (median, 37 months). Tumor recurrence, progression and cancer death were observed in 23, seven and four cases, respectively. The 5-year progression-free rate (75%) and survival rate (83%) in 39 patients with G3 did not show a statistically significant difference from those of the 109 patients with G1 or the 187 patients with G2 superficial bladder cancer who were treated with TUR initially. Only the rate of recurrence of patients with G3 was significantly higher than that of patients with G2 or G1. Adjuvant therapies reduced the recurrence rate of the patients with G3. Only tumor morphology, papillary or non-papillary, affected both the progression-free rate and the survival rate of patients with G3. There were no statistically significant differences associated with other factors. Conclusion: The results suggest that superficial G3 bladder cancer could be treated with TUR initially, especially for papillary tumors.

Original languageEnglish
Pages (from-to)461-465
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume32
Issue number11
DOIs
Publication statusPublished - Nov 1 2002

Fingerprint

Carcinoma in Situ
Urinary Bladder Neoplasms
Neoplasms
Recurrence
Clinical Studies
Conservative Treatment
Therapeutics
Survival Rate
Transitional Cell Carcinoma
Mycobacterium bovis
Disease-Free Survival
Urinary Bladder

Keywords

  • Bladder
  • Superficial bladder cancer
  • Transitional cell carcinoma

ASJC Scopus subject areas

  • Oncology

Cite this

Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy. / Saika, Takashi; Tsushima, Tomoyasu; Nasu, Yasutomo; Arata, Ryoji; Kaku, Haruki; Kusaka, Nobuyuki; Kumon, Hiromi.

In: Japanese Journal of Clinical Oncology, Vol. 32, No. 11, 01.11.2002, p. 461-465.

Research output: Contribution to journalArticle

Saika, Takashi ; Tsushima, Tomoyasu ; Nasu, Yasutomo ; Arata, Ryoji ; Kaku, Haruki ; Kusaka, Nobuyuki ; Kumon, Hiromi. / Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy. In: Japanese Journal of Clinical Oncology. 2002 ; Vol. 32, No. 11. pp. 461-465.
@article{d1b3c4f1268f446a91726f2dd5f4fa0a,
title = "Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy",
abstract = "Objective: The treatment for superficial G3 transitional cell carcinoma (TCC) of the urinary bladder remains controversial. It is important to reveal the clinical features of superficial G3 bladder cancer that can be treated conservatively. Patients and Methods: A total of 39 patients with primary superficial bladder cancer (Ta, T1) with G3 components but without concomitant carcinoma in situ (CIS), who had been treated initially with transurethral resection (TUR), were retrospectively analyzed for factors related to tumor recurrence, progression and survival. The patients were 34 males and five females whose age ranged from 49 to 85 years (average, 68 years). Initial tumor stages were Ta in one patient and T1 in 38. Initial treatments were TUR alone in 18 patients and TUR with adjuvant therapy (intravesical chemotherapy or BCG therapy) in 21. Factors examined included age, gender, morphology, size and number of tumors and adjuvant therapies. Results: Follow-up periods were 3-138 months (median, 37 months). Tumor recurrence, progression and cancer death were observed in 23, seven and four cases, respectively. The 5-year progression-free rate (75{\%}) and survival rate (83{\%}) in 39 patients with G3 did not show a statistically significant difference from those of the 109 patients with G1 or the 187 patients with G2 superficial bladder cancer who were treated with TUR initially. Only the rate of recurrence of patients with G3 was significantly higher than that of patients with G2 or G1. Adjuvant therapies reduced the recurrence rate of the patients with G3. Only tumor morphology, papillary or non-papillary, affected both the progression-free rate and the survival rate of patients with G3. There were no statistically significant differences associated with other factors. Conclusion: The results suggest that superficial G3 bladder cancer could be treated with TUR initially, especially for papillary tumors.",
keywords = "Bladder, Superficial bladder cancer, Transitional cell carcinoma",
author = "Takashi Saika and Tomoyasu Tsushima and Yasutomo Nasu and Ryoji Arata and Haruki Kaku and Nobuyuki Kusaka and Hiromi Kumon",
year = "2002",
month = "11",
day = "1",
doi = "10.1093/jjco/hyf103",
language = "English",
volume = "32",
pages = "461--465",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy

AU - Saika, Takashi

AU - Tsushima, Tomoyasu

AU - Nasu, Yasutomo

AU - Arata, Ryoji

AU - Kaku, Haruki

AU - Kusaka, Nobuyuki

AU - Kumon, Hiromi

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Objective: The treatment for superficial G3 transitional cell carcinoma (TCC) of the urinary bladder remains controversial. It is important to reveal the clinical features of superficial G3 bladder cancer that can be treated conservatively. Patients and Methods: A total of 39 patients with primary superficial bladder cancer (Ta, T1) with G3 components but without concomitant carcinoma in situ (CIS), who had been treated initially with transurethral resection (TUR), were retrospectively analyzed for factors related to tumor recurrence, progression and survival. The patients were 34 males and five females whose age ranged from 49 to 85 years (average, 68 years). Initial tumor stages were Ta in one patient and T1 in 38. Initial treatments were TUR alone in 18 patients and TUR with adjuvant therapy (intravesical chemotherapy or BCG therapy) in 21. Factors examined included age, gender, morphology, size and number of tumors and adjuvant therapies. Results: Follow-up periods were 3-138 months (median, 37 months). Tumor recurrence, progression and cancer death were observed in 23, seven and four cases, respectively. The 5-year progression-free rate (75%) and survival rate (83%) in 39 patients with G3 did not show a statistically significant difference from those of the 109 patients with G1 or the 187 patients with G2 superficial bladder cancer who were treated with TUR initially. Only the rate of recurrence of patients with G3 was significantly higher than that of patients with G2 or G1. Adjuvant therapies reduced the recurrence rate of the patients with G3. Only tumor morphology, papillary or non-papillary, affected both the progression-free rate and the survival rate of patients with G3. There were no statistically significant differences associated with other factors. Conclusion: The results suggest that superficial G3 bladder cancer could be treated with TUR initially, especially for papillary tumors.

AB - Objective: The treatment for superficial G3 transitional cell carcinoma (TCC) of the urinary bladder remains controversial. It is important to reveal the clinical features of superficial G3 bladder cancer that can be treated conservatively. Patients and Methods: A total of 39 patients with primary superficial bladder cancer (Ta, T1) with G3 components but without concomitant carcinoma in situ (CIS), who had been treated initially with transurethral resection (TUR), were retrospectively analyzed for factors related to tumor recurrence, progression and survival. The patients were 34 males and five females whose age ranged from 49 to 85 years (average, 68 years). Initial tumor stages were Ta in one patient and T1 in 38. Initial treatments were TUR alone in 18 patients and TUR with adjuvant therapy (intravesical chemotherapy or BCG therapy) in 21. Factors examined included age, gender, morphology, size and number of tumors and adjuvant therapies. Results: Follow-up periods were 3-138 months (median, 37 months). Tumor recurrence, progression and cancer death were observed in 23, seven and four cases, respectively. The 5-year progression-free rate (75%) and survival rate (83%) in 39 patients with G3 did not show a statistically significant difference from those of the 109 patients with G1 or the 187 patients with G2 superficial bladder cancer who were treated with TUR initially. Only the rate of recurrence of patients with G3 was significantly higher than that of patients with G2 or G1. Adjuvant therapies reduced the recurrence rate of the patients with G3. Only tumor morphology, papillary or non-papillary, affected both the progression-free rate and the survival rate of patients with G3. There were no statistically significant differences associated with other factors. Conclusion: The results suggest that superficial G3 bladder cancer could be treated with TUR initially, especially for papillary tumors.

KW - Bladder

KW - Superficial bladder cancer

KW - Transitional cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0036832103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036832103&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyf103

DO - 10.1093/jjco/hyf103

M3 - Article

C2 - 12499418

AN - SCOPUS:0036832103

VL - 32

SP - 461

EP - 465

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 11

ER -